BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 9, Pages 1861-1871
Publisher
Springer Nature
Online
2014-02-24
DOI
10.1038/leu.2014.81
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor
- (2013) A. R. Chakraborty et al. BLOOD
- Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts
- (2013) S L Locatelli et al. LEUKEMIA
- Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells
- (2013) Carmelo Carlo-Stella et al. PLoS One
- Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma
- (2012) E. Tiacci et al. BLOOD
- Phase II study of sorafenib in patients with relapsed or refractory lymphoma
- (2012) Anna Guidetti et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo
- (2012) R. Coriat et al. MOLECULAR CANCER THERAPEUTICS
- Novel Agents in Hodgkin Lymphoma
- (2012) Alison J. Moskowitz Current Oncology Reports
- Necroptosis: An emerging form of programmed cell death
- (2011) Wei Wu et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
- (2011) Anas Younes et al. LANCET ONCOLOGY
- Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
- (2011) Luca A. Petruccelli et al. PLoS One
- Emerging drugs for Hodgkin's lymphoma
- (2010) Boris Böll et al. EXPERT OPINION ON EMERGING DRUGS
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
- (2010) Michael Dickinson et al. INVESTIGATIONAL NEW DRUGS
- Role of Bim in diallyl trisulfide-induced cytotoxicity in human cancer cells
- (2010) Byeong-Chel Lee et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Developments in the management of Hodgkin's lymphoma
- (2010) Lisa Lowry et al. LANCET
- Beyond chemotherapy: new agents for targeted treatment of lymphoma
- (2010) Anas Younes Nature Reviews Clinical Oncology
- Molecular mechanisms of necroptosis: an ordered cellular explosion
- (2010) Peter Vandenabeele et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR Signaling and Drug Discovery
- (2010) Georg Lurje et al. ONCOLOGY
- Bcl2 family proteins in carcinogenesis and the treatment of cancer
- (2009) Anna Frenzel et al. APOPTOSIS
- New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue
- (2009) Jeannine C. Franke et al. BIOCHEMICAL PHARMACOLOGY
- Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
- (2009) Alison J. Moskowitz et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rational Combinations Using HDAC Inhibitors
- (2009) M. Bots et al. CLINICAL CANCER RESEARCH
- PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells
- (2009) S. Bhalla et al. CLINICAL CANCER RESEARCH
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells
- (2009) U. M. Schneiders et al. MOLECULAR CANCER THERAPEUTICS
- Tumour cell survival signalling by the ERK1/2 pathway
- (2008) K Balmanno et al. CELL DEATH AND DIFFERENTIATION
- Histone deacetylase inhibitors in lymphoma and solid malignancies
- (2008) Walid Rasheed et al. Expert Review of Anticancer Therapy
- Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant
- (2008) M. Crump Hematology-American Society of Hematology Education Program
- The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
- (2007) P. G. Longo et al. BLOOD
- The BCL-2 protein family: opposing activities that mediate cell death
- (2007) Richard J. Youle et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search